Sana Non Current Liabilities Total from 2010 to 2024
| SANA Stock | USD 2.61 0.26 11.06% |
Non Current Liabilities Total | First Reported 2010-12-31 | Previous Quarter 213.3 M | Current Value 324.1 M | Quarterly Volatility 292.8 M |
Check Sana Biotechnology financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Sana Biotechnology's main balance sheet or income statement drivers, such as Depreciation And Amortization of 25.8 M, Interest Expense of 18.9 M or Selling General Administrative of 46.5 M, as well as many indicators such as Price To Sales Ratio of 0.0, Dividend Yield of 0.0 or PTB Ratio of 2.9. Sana financial statements analysis is a perfect complement when working with Sana Biotechnology Valuation or Volatility modules.
Sana | Non Current Liabilities Total |
Latest Sana Biotechnology's Non Current Liabilities Total Growth Pattern
Below is the plot of the Non Current Liabilities Total of Sana Biotechnology over the last few years. It is Sana Biotechnology's Non Current Liabilities Total historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Sana Biotechnology's overall financial position and show how it may be relating to other accounts over time.
| Non Current Liabilities Total | 10 Years Trend |
|
Non Current Liabilities Total |
| Timeline |
Sana Non Current Liabilities Total Regression Statistics
| Arithmetic Mean | 208,072,093 | |
| Geometric Mean | 105,812,720 | |
| Coefficient Of Variation | 140.72 | |
| Mean Deviation | 194,803,312 | |
| Median | 45,736,000 | |
| Standard Deviation | 292,799,387 | |
| Sample Variance | 85731.5T | |
| Range | 1.1B | |
| R-Value | 0.49 | |
| Mean Square Error | 69989.1T | |
| R-Squared | 0.24 | |
| Significance | 0.06 | |
| Slope | 32,203,717 | |
| Total Sum of Squares | 1200240.7T |
Sana Non Current Liabilities Total History
About Sana Biotechnology Financial Statements
Sana Biotechnology stakeholders use historical fundamental indicators, such as Sana Biotechnology's Non Current Liabilities Total, to determine how well the company is positioned to perform in the future. Although Sana Biotechnology investors may analyze each financial statement separately, they are all interrelated. For example, changes in Sana Biotechnology's assets and liabilities are reflected in the revenues and expenses on Sana Biotechnology's income statement, which ultimately affect the company's gains or losses. Understanding these patterns can help in making the right long-term investment decisions in Sana Biotechnology. Please read more on our technical analysis and fundamental analysis pages.
| Last Reported | Projected for Next Year | ||
| Non Current Liabilities Total | 213.3 M | 324.1 M |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.When determining whether Sana Biotechnology offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Sana Biotechnology's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Sana Biotechnology Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Sana Biotechnology Stock:Check out the analysis of Sana Biotechnology Correlation against competitors. For information on how to trade Sana Stock refer to our How to Trade Sana Stock guide.You can also try the Portfolio Center module to all portfolio management and optimization tools to improve performance of your portfolios.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Sana Biotechnology. If investors know Sana will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Sana Biotechnology listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (1.40) | Return On Assets (0.31) | Return On Equity (0.93) |
The market value of Sana Biotechnology is measured differently than its book value, which is the value of Sana that is recorded on the company's balance sheet. Investors also form their own opinion of Sana Biotechnology's value that differs from its market value or its book value, called intrinsic value, which is Sana Biotechnology's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Sana Biotechnology's market value can be influenced by many factors that don't directly affect Sana Biotechnology's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Sana Biotechnology's value and its price as these two are different measures arrived at by different means. Investors typically determine if Sana Biotechnology is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Sana Biotechnology's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.